Format

Send to

Choose Destination
See comment in PubMed Commons below
Lung Cancer. 2013 Sep;81(3):311-8. doi: 10.1016/j.lungcan.2013.05.014. Epub 2013 Jun 18.

The role of epigenetics in malignant pleural mesothelioma.

Author information

1
Molecular and Cellular Epigenetics (GIGA-Cancer) and Molecular Biology (GxABT), University of Liège (ULg), Liège, Belgium.

Abstract

Malignant pleural mesothelioma (MPM) is an almost invariably fatal cancer of the pleura due to asbestos exposure. Increasing evidence indicates that unresponsiveness to chemotherapy is due to epigenetic errors leading to inadequate gene expression in tumor cells. The availability of compounds that modulate epigenetic modifications, such as histone acetylation or DNA methylation, offers new prospects for treatment of MPM. Here, we review latest findings on epigenetics in mesothelioma and present novel strategies for promising epigenetic therapies.

KEYWORDS:

DNA methylation; Epigenetics; Histone acetylation; Mesothelioma

PMID:
23790315
DOI:
10.1016/j.lungcan.2013.05.014
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center